cyc 202 has been researched along with 7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine in 3 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine) | Trials (7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine) | Recent Studies (post-2010) (7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 9 | 0 | 3 |
| Protein | Taxonomy | cyc 202 (IC50) | 7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine (IC50) |
|---|---|---|---|
| Glycogen synthase kinase-3 beta | Sus scrofa (pig) | 0.65 | |
| [Tau protein] kinase | Sus scrofa (pig) | 0.65 | |
| G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 0.15 | |
| G1/S-specific cyclin-E2 | Homo sapiens (human) | 0.4 | |
| Cyclin-dependent kinase 1 | Saccharomyces cerevisiae S288C | 2.5 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.15 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.15 | |
| G2/mitotic-specific cyclin-B | Marthasterias glacialis (spiny starfish) | 0.3333 | |
| Glycogen synthase kinase-3 beta | Rattus norvegicus (Norway rat) | 0.3333 | |
| Cyclin-A2 | Homo sapiens (human) | 0.12 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.4 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.26 | |
| Mitogen-activated protein kinase 8 | Homo sapiens (human) | 3.3 | |
| Mitogen-activated protein kinase 9 | Homo sapiens (human) | 3.3 | |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 0.8239 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.9326 | |
| Mitogen-activated protein kinase 10 | Homo sapiens (human) | 3.3 | |
| Cyclin-A1 | Homo sapiens (human) | 0.12 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.245 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.245 | |
| G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 0.15 | |
| Cyclin-dependent kinase 1 | Oryzias latipes (Japanese medaka) | 0.3333 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crovace, C; Mapelli, M; Massimiliano, L; Meijer, L; Musacchio, A; Seeliger, MA; Tsai, LH | 1 |
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Cheng, W; Kan, Q; Li, Y; Tian, X; Wang, S; Wei, H; Yang, Z | 1 |
1 review(s) available for cyc 202 and 7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine
| Article | Year |
|---|---|
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.
Topics: Animals; Crystallography, X-Ray; Cyclin-Dependent Kinases; Humans; Molecular Structure; Protein Binding; Protein Kinase Inhibitors | 2019 |
2 other study(ies) available for cyc 202 and 7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine
| Article | Year |
|---|---|
Mechanism of CDK5/p25 binding by CDK inhibitors.
Topics: Crystallography, X-Ray; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Indoles; Models, Molecular; Molecular Conformation; Nerve Tissue Proteins; Oximes; Protein Binding; Purines; Roscovitine; Stereoisomerism | 2005 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |